
KYNB Stock Forecast & Price Target
KYNB Analyst Ratings
Bulls say
Kyntra Bio is viewed favorably because it has made a disciplined strategic reset by discontinuing the FG-3246 and FG-3180 oncology programs after insufficient efficacy, which should save upwards of $20 million over the next two years and allow capital to be concentrated on roxadustat. Roxadustat is the more compelling fundamental asset, with preliminary activity in anemia associated with lower-risk MDS, including an exploratory signal in high transfusion burden patients, a favorable safety and tolerability profile, and a pivotal Phase 3 plan targeting about 200 patients with an oral dosing regimen. The balance sheet also supports the thesis, as the company reported $44.1 million in cash with expected runway into 2028, while the royalty restructuring lifted pro forma cash to approximately $53 million and extended runway into 4Q27, improving execution flexibility.
Bears say
Kyntra Bio is facing a materially weaker outlook because a planned interim analysis of its FG-3246 Phase 2 trial showed insufficient efficacy, undermining confidence in its oncology pipeline. The company has now discontinued development of both FG-3246 and FG-3180, which reduces the number of potential value drivers and raises the risk that future clinical catalysts will be limited. With the pipeline already concentrated in high-risk development-stage assets, this setback materially worsens the fundamental case by shrinking optionality and increasing reliance on remaining programs to offset the loss.
This aggregate rating is based on analysts' research of Kyntra Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
KYNB Analyst Forecast & Price Prediction
Start investing in KYNB
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kyntra Bio Inc (KYNB) Forecast
KYNB Analyst Forecast & Price Prediction
Start investing in KYNB
Order type
Buy in
Order amount
Est. shares
0 shares